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Urticaria pigmentosa (mastocytosis cutis),
usually a benign dermatosis, typically consists of
numerous small brown macules scattered pri-
marily over the trunk. Histologically, there is a
diagnostic mast cell infiltrate of the upper corium.
Mild trauma causes urtication of the lesions
(Darier's sign), a result of histamine release by
the mast cells. As first demonstrated by Pernow
and Waldenstrom (1) patients with this disease
characteristically excrete increased amounts of
histamine in the urine.
The histaminuria presumably results from
simple overproduction of histamine by the in-
creased number of mast cells. Prior studies (2)
have demonstrated the presence, in human mast
cells of urtiearia pigmentosa (H.P.), of an enzyme
(histidine decarboxylase) capable of converting
the amino acid histidine to histamine. In addition,
oral administration of Carbon'4-labelled histidine
to two patients with H.P. has suggested the
histaminuria to be a result of overproduction
rather than an abnormality of histamine deg-
radative processes.
The present investigation undertakes further
studies of the deearboxylase enzyme present in
the human mast cells of H.P. Carbon'4-labelled
histamine has been administered intradermally to
two patients with urtiearia pigmentosa and to two
normal volunteer subjects. Assay of the urine for
histamine and its metabolic products was per-
formed.
These studies have demonstrated the striking
specificity of the enzyme histidine deearboxylase
found in human mast cells of H.P., and have
shown the histamine degradative pathway to be
intact in patients with urtiearia pigmentosa. In an
attempt to estimate the size of the metabolic pool
of histamine, trace quantities of radioactive
histidine have been given intravenously to two
patients with urticaria pigmentosa and to two
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healthy volunteers. Estimates of the amount of
histamine metabolized, amounts present in
lesions and uninvolved skin, and histamine turn-
over time have been made. These estimates pro-
vide suggestive evidence that even apparently
simple eases of H.P. (Mastoeytosis eutis (3)) may
represent diffuse mastocytosis).
METHODS
DECARBOXTLA5E Activity: Homogenates of
the biopsy specimens were prepared in ice-cold
Tyrode's solution, additions were made, and the
mixture incubated using technies previously
described (2).
Histidine decarboxylase activity was determined
following incubation of the homogenates with
radioactive histidine and separation of radio-
active histamine by paper and column chroma-
tography (2).
5-hydroxytryptophan decarboxylase activity was
established following incubation of homogenates
with 5-hydroxytryptophan-3-C'4 (Nuclear Chi-
cago Corp.). Radioactive 5-hydroxytryptamine
(serotonin) was separated out by paper chroma-
tography, using a solvent system of isopropanol
(10 parts):10 per cent ammonium hydroxide
(3 parts). With this solvent system the Rf value
for 5-hydroxytryptophan was 0.19 and the R1
value for serotonin was 0.62, allowing adequate
separation. The area of the chromatograms
corresponding to that of serotonin was eluted
and the radioactivity measured in a liquid scin-
tillation counter.
Dopa decarboxylase activity: The homogenates
were incubated with DL-3(3,4-dihydroxyphenyl)-
alanine-2-C'4 (DOPA-C'4) (Nuclear Chicago
Corp.). Radioactive dopamine (dihydroxyphenyl-
ethylamine) was separated by chromatographie
methods previously described (4), followed by
elution and measurement of radioactivity in a
liquid scintillation counter.
URINARy HIsTAMINE: Urinary excretion of free
histamine was estimated by the method of Duner
and Pernow (5); in our laboratory the excretion
by normal adult subjects ranged from 5 to 30
micrograms of free histamine in 24 hours (3).
Ti S5UE HIsTAMINE: The histamine content of
skin and skin lesions was determined using the
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procedure described by Johnson (6). The sub-
cutaneous layer was trimmed away from fresh
biopsy specimens taken from the back, the tissue
weighed, minced and ground with cold 5% tn-
chloracetie acid and sand, centrifuged and the
histamine content determined by the method of
Lowry et al. (7).
III5TA'.sINE METABOLISM: Histamine-2-C'4 was
administered to two patients with urticaria pig-
mentosa and to two volunteer normal subjects
using the technic originally developed by
Schayer and Cooper (8). All medications were
withheld for three weeks, and neither food nor
liquids were given during the 12 hours immedi-
ately prior to the experiment. The subjects re-
ceived intradermally L-histamine-2-C4 (specific
activity 6.81 mC/mM, Nuclear Chicago Corp.),
prepared as a sterile isotonic saline solution.
Plasme Clearance: Total plasma radioactivity
was determined by the method of Beall and Van
Arsdel (9) with minor modifications; plasma was
separated centrifugally from 30 ml. venous blood
samples, deproteinized with trichloroacetic acid
(30%), buffered with sodium acetate (4M), and
counted in a Packard Tri-Carb liquid scintillation
counter. Plasma histamine was measured by the
isotope dilution technic following preparation
of the dipicrate (see below).
Urinary Excretion: Urine was voided immedi-
ately before the injections and was then collected
for the following 24 hours, assayed for total
radioactivity, histamine, and histamine me-
tabolites using primarily the methods outlined by
Schayer and Cooper (8).
Total radioactivity of the urine was established
by use of internal standards (8). The urinary
excretion of radioactive histamine and metabo-
lites was determined by the isotope dilution
technique following preparation of the picrate
derivative and multiple recrystallizations. C'4-
histamine was determined by addition of non-
radioactive carrier histamine (400 mg., K and K
Laboratories), preparation of the dipicrate, and
repeated recrystallization. Following each re-
crystallization the yellow picric acid was re-
moved with toluene (10) and radioactivity was
determined in a liquid scintillation counter;
recrystallization was repeated until constant
specific activity was achieved. C'4-imidazole
acetic acid (free) was similarly determined;
carrier imidazole acetic acid (400 mg., K and K
Laboratories) was added and the dipicrate pre-
pared and recrystallized several times with norite
and charcoal until constant specific activity was
achieved. C'4-methylimidazole acetic acid was
determined in a similar fashion following con-
version to the picrate. Carrier 1,4-methylimida-
zole acetic acid' was added, the picrate formed
and recrystallized until constant specific activity
obtained. Prior to determinations of specific
activity, the melting point of each derivative was
established. An average of six recrystallizations
(between 4 and 9) was required for each of the
compounds in order to achieve constant specific
activity.
lladioautograms of urinary C" metabolites of
histamine were prepared following two-dimen-
sional ascending paper chromatographic separa-
tion. The technics described by Beall and
VanArsdel (14) were followed with slight modifi-
cation. Methanol extracts of 20 ml. aliquots of
urine were chromatographed using n-butanol
80:ethanol 10:concentrated NH,OH 30 and n-
butanol 40:acetic acid 10:water 5 as solvents.
Kodak gravure copy film was exposed to the
chromatograms for 2—4 weeks.
HI5TIOINE METABOLISM: L-histidine-2-C" (spe-
cific activity 2.1 mC/mM, Nuclear Chicago Corp.),
was administered intravenously as a sterile
isotonic saline solution to two patients with
urticaria pigmentosa and to two volunteer control
subjects. The technics employed were essen-
tially identical with those used following oral
administration of radioactive histidine and have
been described in detail previously (2, 15). Total
radioactivity of the urine and the urinary excre-
tion of radioactive histidine, histamine, and the
metabolites, imidazole acetic acid (free) and 1,4-
methylimidazole acetic acid were determined as
described above.
One day after radiohistidine administration,
biopsies of the U.P. skin lesions and of skin from
the backs of the controls were extracted with
trichloracetic acid (as described for tissue hista-
mine), centrifuged and neutralized. Total radio-
activity and (following the addition of carrier
and preparation of the dipicrate), histamine
radioactivity were determined in a liquid scin-
tillation counter.
RESULTS
IDEcARBOXvLASE EXPERIMENTS: As has been
reported previously (2), homogenates of the skin
lesions of urticaria pigmentosa produced signifi-
cant amounts of histamine from radioactive histi-
dine. When homogenates were incubated under
identical conditions with Carbon'4-laheled dopa
or 5-hydroxytryptophan there was no appreciable
decarboxylation of either of these compounds
(Table I). While the technics employed do not
preclude the possibility that trace quantities may
'Synthesized according to the method of Pyman(11) as modified by Bauer and Tahor (12) and
Karjala and Turnquest (13).
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have formed, it is clear that oniy negligible
amounts of serotonin or dopamine were produced
either by homogenates of skin lesions of UP.,
containing many mast cells, or by uninvolved
skin which contains relatively few mast cells.
These findings demonstrate a high degree of sub-
strate specificity of the amino acid decarboxylase
present in human mastocytomas unlike the de-
carboxylases found in mastocytomas of other
species (16). Studies designed to characterize this
enzyme further are in progress and will be re-
ported later.
HISTAMINE METABOLISM: Histamine metabo-
TABLE I
Rate of formation of amines by skin homogenates of
urticaria pigmentosa
Amine Formed (micro-
grams/gm. skin/3 hours)
thiin-Lesions volved skin
lism was studied in two patients with urticaria
pigmentosa and two volunteer control subjects.
Radioactive histamine was slowly injected intra-
dermally over a 20-minute period. Subjects re-
ceived approximately 1 y/Kg. body weight, or
between 55 and 70 micrograms of histamine (ex-
pressed as the free base).
One patient with urticaria pigmentosa and one
of the control subjects experienced no symptoms
of any kind following injection. One patient with
urticaria pigmentosa (male) developed a moder-
ately severe occipital headache which persisted
for about three hours following injection. One
control subject developed an erythematous flush
which began in the blush area, gradually spread-
ing to cover most of the upper part of her body,
and persisting for about 20 minutes. She also ex-
perienced a persistent occipital headache. None of
the subjects developed tachycardia, hypotension,
or other symptoms.
Plasma clearance: Plasma levels of total radio-
activity and free histamine radioactivity were de-
20 termined after the intradermal administration of
radioactive histamine (Fig. 1). The concentration
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FIG. 1. Time course of plasma clearance of total radioactivity and histamine radioactivity following
intradermal administration of C1Shistamine to urticaria pigmentosa patients and controls.
Two patients with urticaria pigmentosa and two control subjects were studied. Radioactive histamine
was slowly injected intradermally over a 20 minute period ending at time 0 minutes. There was no sig-
nificant difference between patients and controls, hence the curves have been drawn through the average
values. Vertical lines indicate the range of values obtained.
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TABLE II
Per cent of intradermally injected C'4 histamine recovered from the urine as histamine and metabolites
0—6 hrs. 6.42 hrs. 12—24 hrs. 0—24 hrs.
Control U.P. Control V.P. Control
0.1
0.0
0.1
V.P.
0.1
0.0
0.1
Control
2.6
1.6
2.1
V.P.
3.3
2.5
2.9
1Histamine
Average
2.3
1.6
2.0
3.0
2.4
2.7
0.2
0.0
0.1
0.2
0.1
0.2
ía"Imidazole acetic acid (free)
Average
9.7
8.3
9.0
13.7
9.5
11.6
1.7
1.6
1.7
1.1
3.4
2.3
1.9
0.4
1.2
1.5
1.2
1.4
13.3
10.3
11.8
16.3
14.1
15.2
1,4-Methylimidazole acetic f
acid
Average
26.2
33.0
29.6
44.7
25.2
34.9
8.8
11.0
9.9
6.9
12.7
9.8
3.1
6.8
4.5
6.6
4.1
5.4
38.1
50.8
44.4
58.2
42.0
50.1
ía"Total radioactivity
Average
66.9
59.9
63.4
80.5
56.0
68.3
13.7
15.0
14.4
9.8
18.2
14.0
7.0
8.8
7.9
11.1
9.0
10.1
87.6
83.7
85.7
101.4
83.2
92.3
Nonradioactive free hista- 5 a"
mine (y/day)*
23
19
180
220
* Total urinary excretion of nonradioactive free histamine was estimated on the basis of amount
excreted in the 12 to 24 hour specimen. Urinary excretion of free histamine by normal adult subjects
ranged from 5 to 30 micrograms in 24 hours.
with time, though a trace persisted after 24 hours.
Free histamine disappeared rapidly from the
plasma; there were only negligible amounts de-
tected 2 hours after completion of the injection.
Persisting radioactivity can, on the basis of the
urinary finding, be attributed almost exclusively
to histamine metabolites. There was no signifi-
cant difference in the clearance rate of total
radioactivity or of free histamine from the plasma
either of patients or controls. For this reason the
data has been presented as averages in Figure 1.
The wide range of values reflects, in part, the
great individual variations in histamine metabo-
lism.
Urinary excrtion: The total amount of radio-
activity excreted in the urine as well as the radio-
activity present in the histamine, free imidazole
acetic acid, and 1 ,4-methylimidazole acetic acid
fractions is shown in Table II. There was no evi-
dence of prolonged histamine binding by U.P.
patients, nor was there a significant difference in
the excretion of radioactivity between U.P. pa-
tients and control subjects. Both patients and
control subjects excreted approximately 3 of
the administered radioactivity within six hours
after intradermal administration. Almost 90 per
cent of the radioactivity was excreted within 24
hours. Of particular note is the fact that the ex-
cretion of free histamine radioactivity was es-
sentially the same in control subjects as in pa-
tients. In both groups (Table II) between 2 and
3 per cent of the administered histamine was
excreted in the urine as free histamine. On the
other hand, the endogenous excretion of non-
radioactive free histamine by control subjects
was within the normal range for this laboratory
(3), while the histamine excretion of the two
U.P. patients (Table II) was significantly ele-
vated on the day in which their metabolism of
labeled histamine was determined.
Two-dimensional paper chromatography fol-
lowed by radioautography of methanol extracts
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of the urine specimens revealed only three distinct
darkened areas. Using internal standards, ob-
tained by adding non-radioactive compounds to
the methanol extracts prior to radioautography,
it was possible to identify the radioactive areas as
imidazole acetic acid, ribosyl imidazole acetic
acid, and 1 ,4-methylimidazole acetic acid. No
distinct radioactivity could be detected in the
histamine or 1 ,4-methyl histamine areas. In ad-
dition, the radioautograms provided no evidence
of the formation of hitherto unknown metabolites
of histamine by patients with urticaria pig-
mentosa.
The principal urinary metabolite found under
the conditions of these experiments was 1,4-
methylimidazole acetic acid, accounting for ap-
proximately one half of the total radioactivity
excreted by controls and patients with U.P.
HISTIDINE METABOLISM: The metabolism of
intravenously administered histidine was studied
in two patients with urticaria pigmentosa and two
volunteer controls. Subjects received only one
dose of 250 y (approximately 4 'y/Kg. body
weight) of radioactive histidine. None of the sub-
jects experienced any symptoms following in-
jection.
Urinary excretion: The total radioactivity ex-
creted in the urine within the first 24 hours follow-
ing administration, as well as the radioactivity
present in the histidine, free imidazole acetic acid,
1,4 METHYLIMIDAZOLE
ACETIC ACID
histamine and 1, 4-methylimidazole acetic acid
fractions is shown in Table III (day 1). The
amount excreted by patients and controls was
not significantly different; both excreted approxi-
mately 6 per cent of the injected radioactivity
within the first 24 hours. Histidine (presumably
excreted unchanged) accounted for about j-4 of
the radioactivity. A significant amount of free
imidazole acetic acid, presumably converted di-
rectly from histidine (Fig. 2), was also detected
in the urine.
Following intravenous injection, as with orally
administered histidine-C'4 (2), it was not possible
to detect significant amounts of histamine in the
urine of either control subjects or U.P. patients,
nor could significant amounts of the specific
metabolite of histamine, 1, 4-methylimidazole
acetic acid, be found. This is of particular interest
since on the days when radioactive histidine was
administered, the patients with U.P. showed
significant histaminuria, as contrasted with con-
trols.
The urine of the UP. patients as well as the
control subjects was also collected over a five
hour period on the day following the intravenous
administration of radioactive histidine. Urine col-
lections were made with the control subjects
ambulant but without exertion (sitting and read-
ing). By contrast, the patients with U.P. took a
fifteen minute hot shower immediately followed by
IMIDAZOLEACETIC
ACID
HISTIDINE
HISTAMINE
1,4 METHYLHISTAMINE
HC=C—CH2—CH —NH2II \
HN N COOH
"C1
I
HC
HN N
I
HC = C— CH2 —CH2 —NH2
CH3—N N
H
'I,
HC =C—CH2—COQH
lU rU/\
CH3 C
H
FIGURE 2
HC C—CH2 COOH
HN N
Jr
518 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
TABLE III
Per cent of intravenous injected G'4-histidine
recovered from the urine as metabolites of histidine
Control
0-24 hrs. 0—5 hrs.
dayl day2
U.P.
0—24 hrs. 0—5 hrs.
dayl day2*
Histidine
Imidazole acetic
acid (free)
Histamine
1 ,4-Methylimidazole
acetic acid
Total radioactivity.
1.87
0.248
<0.05
<0.05
5.23
<0.05 2.03
<0.05 0.195
<0.05 <0.05
<0.05 <0.05
0.42 6.29
<0.05
<0.05
<0.05
<0.05
0.37
* Whealing of the skin lesions was induced by
showering, vigorous towelling and mechanical
trauma.
vigorous towelling of the lesions and subsequently
an attempt was made to mechanically traumatize
each one of the accessible lesions by exerting
moderate pressure with a wooden tongue de-
pressor. This stimulus produced whealing of the
individual lesions and a diffuse erythroderma in
both patients. One patient experienced bright red
flushing of the face and a bout of midepigastrie
pain with dull occipital headache. Following this
stimulation the urine was again collected over a
5 hour period and assayed as shown in Table III
(day 2). Despite stimulation and the clinically
obvious release of histamine by the mast cells of
the TIP, skin lesions, there was (Table III) no
significant difference in the total amount of
radioactivity excreted in the urine, nor could any
radioactive free histamine or 1, 4-methylimidazole
acetic acid be found in the urine of patients with
TI.P.
On the day following the intraveuous adminis-
tration of carbon-labeled histidine, two biopsies
were taken from each of the controls and from
skin lesions of patients with TJ.P. (prior to stimu-
lation). No significant amount of radioactivity
was demonstrated in any of the biopsies, either in
terms of total radioactivity present or as free
histamine. This failure to detect conversion of
histidine to histamine can probably best be ex-
plained by the fact that the histamine pathway of
histidine metabolism is relatively insignificant in
contrast to the overall metabolism of histidine.
DISCUSSION
The amino acid decarboxylase enzyme of
human mast cells of urticaria pigmentosa (U.P.)
has a high degree of substrate specificity for histi-
dine. This specificity is not an inherent character-
istic of mast cell decarboxylases, for the mastocy-
tomas of other species have been shown to possess
enzymic decarboxylase activity for 5-hydroxy-
tryptophan and dihydroxyphenylalanine (16).
The inability of homogenates of skin lesions to
produce serotonin by deearboxylation provides
further evidence of the absence of serotonin in the
mast cells of U.P. The human mast cell apparently
contains significant amounts of only one bio-
logically active amine — histamine.
While all of the known metabolites of histamine
(Figure 2) were not evaluated, the results of the
C14-histamine excretion studies eliminate the pos-
sibility that the increased urinary excretion of
free histamine is due to a block in the degradative
pathway of histamine. Had any hypothetical
block, reduction or absence of one or more of the
normal degradative steps existed, then one could
have anticipated that the relative recovery of
radioactive histamine, imidazole acetic acid, or
1, 4-methylimidazole acetic acid would have been
significantly different in patients with urtiearia
pigmentosa as compared to controls. Thus the
conclusion that the histaminuria characteristic of
urticaria pigmentosa is the result of overproduc-
tion of histamine becomes inescapable.
The finding that 1 ,4-methylimidazole acetic
acid is the principal urinary metabolite of hista-
mine is in agreement with the findings of other
investigators, including Schayer and Cooper (8),
Lindell et al. (17), and Lindell, Nilsson and
Rorsman (18), who have employed similar tech-
niques to study histamine metabolism in humans.
Beall and VanArsdel (14) determined the princi-
ple human metabolite to be imidazole acetic acid;
however, they used a less specific method than the
isotope dilution technic.
The ratio of urinary excretion of histamine to
1 ,4-methylimidazole acetic acid, as can be seen
from Table II, is approximately 1 to 18. Conse-
quently, when histaminuria is detected in urti-
earia pigmentosa, there should be a corresponding
1, 4-methylimidazole acetic aciduria of the same
magnitude. This is apparently the case, for we
have been able to identify greatly increased quan-
tities of 1 ,4-methylimidazole acetic acid in the
urine of patients with urtiearia pigmentosa as con-
trasted with control subjects. These findings are
to be reported in detail (19).
Although attempts with C'4-histidine to label
the histamine metabolic pool of urtiearia pig-
mentosa have been unsuccessful to date, some
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TABLE IV
1 2 3 4 5 6 7 8 9 10 11
Free
Excretion
(y/day)
Hista-
Excreted
Free
(%)
Hista-
m
olized
(mg/day)
u
Lesions
Average
Diameter
Lesions
(mm.)
lli1ta-
Content
Skin
TTi7ta-
Content
Skin
''g°
Conthflt
volved
Skin
Hita-
Content
Skin
A
S
Hi1ta-
mine
over
Extracu-
taneous
mine
A7umd
Control r3'... 23
Control 9... 19
2.6
1.6
0.88
1.18
—
—
—
—
—
—
—
—
7.0
8.4
30.1
28.9
0
s
34.1+
24.5+
9.4+
11.0+
—
—
134.2
118.2
U.P. ri' 180
UP. 9 220
2.6
3.3
6.91
6.66
3920
1300
2.0
2.5
70.3
37.9
1.8
0.5
16.2
20.9
65.2
73.2
* These figures must be considered as estimates only since they were derived by using histamine
values obtained by different methods of analysis.
estimate of pooi size and turnover time of hista-
mine can be made on the basis of information at
hand. The assumption must be made (and such
assumptions are inherent in virtually all tracer
studies), that endogeaous histamine is metabo-
lized in a fashion similar to the carbon labeled
compound. Thus in two patients with urticaria
pigmentosa and two control subjects to whom
Ct4histamine was administered, the urinary ex-
cretion of nonradioactive free histamine was
determined (Table IV, Col. 1). Using radiohista-
mine, the per cent of histamine which is excreted
as free histamine was determined (Col. 2) and
from these two determinations it was possible to
calculate the quantity of histamine (Col. 3) which
must have been metabolized during this 24 hour
period by these patients.
The number of skin lesions was carefully
counted by several observers (Col. 4) and their
average diameter measured (Col. 5). Analysis of
the histamine content of the skin lesions was per-
formed (Col. 6). The measurements allow estima-
tion of total histamine content of the skin lesions
(Col. 7). As can readily be seen from Cols. 3
and 7, these patients with urticaria pigmeatosa
metabolize daily several times more histamine
than is present in their skin lesions!
The histamine content of the uninvolved skin
of the back and similar areas of controls was
measured (Col. 8) and the total histamine content
of the skin (Col. 9) was calculated on the basis
that these represent average values (20) and that
the skin constitutes 6% of body weight. As can be
seen from Col. 9, the histamine present in the skin
of U.P. patients was approximately twice that of
controls. This can presumably be attributed to an
increased number of mast cells in uninvolved
skin and the increased histidine decarboxylase
activity of this skin (2). The lesions contributed
only a small fraction (<3% in these patients) of
the total skin histamine.
Using these data, it is possible to estimate the
turnover time of histamine provided certain as-
sumptions are made. It must be assumed that
essentially all the histamine in skin can be liber-
ated for metabolism and hence is in a miscible
form. In addition, it must be assumed, at least for
the calculation of histamine turnover time, that
the extracutaneous histamine stores (lung, liver,
gastrointestinal, including gastric stores, etc.) are
of the same size in controls and patients with
urticaria pigmentosa. Then dividing total cutane-
ous histamine content (Col. 9) by the amount of
histamine metabolized daily (Col. 3), provides
an estimate of the histamine turnover time
(H.T.O.T.) (Col. 10). The extracutaneous hista-
mine stores if added to the values for total cu-
taneous histamine (Col. 9) would lengthen the
H.T.O.T. and hence are represented as plus values
(Col. 10).
When the H.T.O.T. for patients with U.P. is
contrasted with controls, there is an apparent
two-fold difference. However, our studies with
Ct4-histidine and histamine suggest (hut do not
conclusively prove) that there is no difference be-
tween these groups in the rate of histamine turn-
over. While the possibility of a difference in turn-
over rates cannot be completely excluded, an
interesting calculation can be made by assuming
that patients with U.P. turn histamine over at a
rate comparable to controls. In order for this to
be true, then one of the prior assumptions (that
the extracutaneous histamine stores were of the
same size) must be invalid. Applying the hista-
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mine turnover time of controls to patients with
IJ.P., the amount of extracutaneous histamine, in
excess of the amounts present in controls, can be
calculated (Col. 11). As can be seen by comparing
Columns 11 and 9, the quantity of extracutaneous
histamine, over and above the amounts present in
controls, in these patients is greater than the total
histamine content of their skin.
Reilly (21) has clearly demonstrated in several
species that the bulk of the histamine content of
most tissues (with the exception of the pyloric
portion of gastric histamine) resides in mast cells.
Hence large stores of extracutaneous histamine
well may reflect extracutaneous mastocytosis.
One of these TJ.P. patients (female) did present
radiological evidence of skeletal lesions, which
may account for the extracutaneous stores. How-
ever, the other TJ.P. patient (male) on careful
study, had no clinical or radiological evidence of
systemic mastocytosis. This observation suggests
that some cases of what is apparently urticaria
pigmentosa (mastocytosis cutis (3), without evi-
dence of systemic mast cell tumors involving
bone, liver, spleen or other organs), may in fact
be a diffuse mastocytosis. It is planned to extend
these studies to other patients with the form of
urticaria pigmentosa (mastocytosis cutis) which
has been viewed as limited to the skin.
SUMMARY AND CONCLUSIONS
Further in vitro and in vivo studies of the
metabolism of histidine and of histamine in urti-
caria pigmentosa (U.P.) are reported. The amino
acid decarboxylase enzyme present in the human
mast cells of U.P. has a high degree of substrate
specificity for histidine while not attacking 5-
hydroxytryptophan or dihydroxyphenylalanine.
Intradermal administration of C'4-histamine to
two patients with UP. experiencing histaminuria
and to two controls has demonstrated the metabo-
lism of histamine to be normal in this disease.
Plasma clearance and urinary excretion of hista-
mine and metabolites were similar in controls and
patients. The principle histamine metabolite was
1 ,4-methylimidazole acetic acid; no unusual
metabolites were excreted by patients with UP.
Intravenously administered C'4-histidine was
metabolized similarly by controls and patients
with UP. The quantity of histamine metabolized
daily and the total skin histamine content have
been approximated. These values suggest that
some cases of UP., without clinical evidence of
systemic involvement (mastocytosis cutis), may
in fact have a diffuse mastocytosis.
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DISCUSSION
Du. JOSEPH McGUIBE. (New Haven, Conn.):
I would like to ask two questions which bear on
the status of bound histamine.
Do you think that the rate limiting factor in
histamine release is histidine decarboxylase? And,
is bound histamine part of the miscible pool? Or,
is this a eompartmented histamine that the in-
jected histamine does not mix with?
Du. D. JOSEPH DEMIS (inclosing): With regard
to Dr. McGuire's questions, histidine decar-
boxylase does not seem to be the rate limiting
factor. This enzyme is, as far as is known, only
involved in histamine synthesis and mast cells
would appear able to synthesize and store more
histamine than is released. Bound histamine is
susceptible to release by a variety of physical and
chemical stimuli, including some which are ap-
parently very mild. The ease of release may be a
direct effect as the result of weak binding or as
has been suggested, may be due to the existence
of a ready mechanism for histamine release which
is easily activated.
Bound histamine is released from its tissue
sites into the circulation and hence is part of the
metabolic pool. Exogenous injected histamine is
rapidly excreted with little prolonged binding by
cells and does not mix with stored endogenous
histamine.
